Trial Profile
A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Haematological malignancies; Lymphoma
- Focus Pharmacokinetics
- Sponsors Genzyme Corporation
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 21 Jan 2011 New trial record